...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: One More Promissory Note-Aug 9/24

One more:

Promissory Note: Dated 2024-08-29 for $ 303,165.00

With 300K warrants @ $1.01 expire, 2029-08-29

Out of Alberta (Accredited Investor)

 

Koo

 

 

Share
New Message
Please login to post a reply